Division of Nephrology, Hypertension and Transplantation, University of Florida, Gainesville, Florida.
Nephrology Section, Department of Medicine, North Florida/South Georgia Veteran Healthcare System, Gainesville, Florida.
Kidney360. 2021 Sep 28;3(1):91-98. doi: 10.34067/KID.0004502021. eCollection 2022 Jan 27.
Pre-ESKD Kidney Disease Education (KDE) has been shown to improve multiple CKD outcomes, but its effect on vascular access outcomes is not well studied. In 2010, Medicare launched KDE reimbursements policy for patients with advanced CKD.
In this retrospective USRDS analysis, we identified all adult patients on incident hemodialysis with ≥6 months of pre-ESKD Medicare coverage during the first 5 years of CMS-KDE policy and divided them into CMS-KDE services recipients (KDE cohort) and nonrecipients (non-KDE cohort). The primary outcome was incident arteriovenous fistula (AVF) and the composite of incident AVF or arteriovenous graft (AVG) utilization. Secondary outcomes were central venous catheter (CVC) with maturing AVF/AVG and pure CVC utilizations. Step-wise multivariate analyses were performed in four progressive models (model 1, KDE alone; model 2, multivariate model encompassing model 1 with sociodemographics; model 3, model 2 with comorbidity and functional status; and model 4, model 3 with pre-ESKD nephrology care).
Of the 211,990 qualifying patients on incident hemodialysis during the study period, 2887 (1%) received KDE services before dialysis initiation. The rates of incident AVF and composite AVF/AVG were more than double (30% and 35%, respectively, compared with 14% and 17%), and pure catheter use about a third lower (40% compared with 65%) in the KDE cohort compared with the non-KDE cohort. The maximally adjusted odds ratios in model 4 for study outcomes were incident AVF use, 1.78, 99% confidence interval, 1.55 to 2.05; incident AVF/AVG use, 1.78, 99% confidence interval, 1.56 to 2.03; incident CVC with maturing AVF/AVG, 1.69, 99% confidence interval, 1.44 to 1.97; and pure CVC without any AVF/AVG, 0.51, 99% confidence interval, 0.45 to 0.58. The benefits of the KDE service were maintained even after accounting for the presence, duration, and facility of ESKD care.
The occurrence of pre-ESRD KDE service is associated with significantly improved incident vascular access outcomes. Targeted studies are needed to examine the effect of KDE on patient engagement and self-efficacy as a cause for improvement in vascular access outcomes.
预先慢性肾脏病(ESKD)肾脏疾病教育(KDE)已被证明可以改善多种慢性肾脏病结局,但它对血管通路结局的影响尚未得到很好的研究。2010 年,医疗保险为晚期慢性肾脏病患者推出了 KDE 报销政策。
在这项回顾性的美国肾脏数据系统(USRDS)分析中,我们确定了在 CMS-KDE 政策实施的前 5 年内,所有在 Medicare 保险下接受初始血液透析且有≥6 个月的预 ESKD 覆盖的成年患者,并将他们分为 CMS-KDE 服务接受者(KDE 队列)和非接受者(非-KDE 队列)。主要结局是新发动静脉瘘(AVF)和新发 AVF 或动静脉移植物(AVG)利用的复合结局。次要结局是带成熟 AVF/AVG 的中心静脉导管(CVC)和纯 CVC 的利用。在四个渐进模型中进行逐步多变量分析(模型 1,KDE 单独;模型 2,包含模型 1 的社会人口统计学的多变量模型;模型 3,包含合并症和功能状态的模型 2;模型 4,包含预 ESKD 肾脏科护理的模型 3)。
在研究期间接受初始血液透析的 211990 名合格患者中,有 2887 名(1%)在透析开始前接受了 KDE 服务。与非-KDE 队列相比,KDE 队列的新发 AVF 和复合 AVF/AVG 发生率高出一倍以上(分别为 30%和 35%,而 14%和 17%),纯导管使用率则降低了约三分之一(40%对 65%)。模型 4 中研究结局的最大调整比值比为新发 AVF 使用率为 1.78,99%置信区间为 1.55 至 2.05;新发 AVF/AVG 使用率为 1.78,99%置信区间为 1.56 至 2.03;带成熟 AVF/AVG 的新发 CVC 使用率为 1.69,99%置信区间为 1.44 至 1.97;无任何 AVF/AVG 的纯 CVC 使用率为 0.51,99%置信区间为 0.45 至 0.58。即使考虑到 ESKD 护理的存在、持续时间和设施,KDE 服务的益处也得以维持。
预先 ESKD KDE 服务的发生与显著改善的新发血管通路结局相关。需要进行针对性研究,以检验 KDE 对患者参与和自我效能的影响,这可能是改善血管通路结局的原因。